3SBIO Aktie

 

3SBIO (01530.HK) announced the physical distribution of all shares of Mandy International, opening today with a 3.36% increase and peaking at HKD25. By midday, the stock closed at HKD24.96, up 10.25%, with a trading volume of 38.3572 million shares and involving a capital of HKD922 million.3SBIO announced a special dividend dist......

SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both......

3SBio (01530.HK) announced its 2025 annual results, reporting revenue of RMB17.696 billion, up 94.3% year-on-year, primarily due to licensing revenue from a breakthrough PD-1/VEGF bispecific antibody 707 licensing deal with Pfizer. The company recorded a net profit of RMB8.482 billion, a growth of 305.8%, with an EPS of RMB3.51.......

3SBio (01530.HK) announced that it will distribute a special dividend through an in-kind distribution, allocating all shares of Mandy International held by the company to eligible shareholders in proportion to their shareholdings before the proposed spin-off is completed.In November last year, the company announced the proposed ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer (PFE.US) earlier disclosed its blockbuster development plan for 707/PF'4404(PD-1/VEGF) in collaboration with 3SBIO (01530.HK), with speed and breadth of advancement exceeding CMBI's expectations, according to CMBI's research report.The broker believed that PD-1/VEGF bispecific antibody will become cornerstone ......

Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on “Bloomberg: The China Show” from San Francisco, where the JPMorgan Healthcare Conference is taking place. (Source: Bloomberg)...

Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 SINO BIOPHARM(01177.HK) | Buy | 9.4 WUXI XDC(02268.HK) | Buy | 74 ~AAStocks Financial NewsWeb Site: www.aastocks.com...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 WUXI XDC(02268.HK) | Buy | 74 SINO BIOPHARM(01177.HK) | Buy | 9.4 ~AAStocks Financial NewsWeb Site: www.aastocks.com...

read more...

After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways:    By Molly Wen Buoyed by a stock rally, Chinese drug developer 3SBio Inc. (1530.HK) is bulking up on funds to meet the challenge of delivering..... The post 3SBio gears up for drugs battle with $400 million equity move appeared first on Bamboo Works....

Chinese drug maker 3SBio plans to raise HK$3.12 billion (US$401 million) by selling a 4.14 per cent stake in the company to fund clinical research in China and the US and expand the global reach of its drug portfolio. The Shenyang-based biopharmaceutical firm has agreed to sell 105.1 million new shares at HK$29.62 each. The placing price represents a 6.5 per cent discount compared with Monday's closing price of HK$31.68, according to its filing with the Hong Kong stock exchange on Tuesday. The......

3SBIO (01530.HK) plans a share placement at a 6.5% discount, with net proceeds reaching HKD3.087 billion. This news dented the company's stock price by 3.09% at open today (2nd), bottoming at HKD29.98. It last traded at HKD30.04, down 5.18%, with a trading volume of 4.6345 million shares, amounting to HKD140 million.3SBIO an......

3SBIO (01530.HK) announced plans to place over 105 million shares, representing approximately 4.14% of the enlarged issued share capital, at a placement price of HKD29.62 per share, which is a 6.5% discount to the previous trading day's closing price of HKD31.68. The net proceeds are expected to reach HKD3.087 billion.Approx......

Mandi, the Alibaba Health-backed consumer healthcare arm being spun off from mainland drug maker 3SBio, filed for an initial public offering in Hong Kong on Friday, betting that its market-leading minoxidil hair-loss products will attract investors. The deal aims to tap into a red-hot Hong Kong market that has seen US$73 billion in equity capital market activity this year, a 232 per cent surge from the same period in 2024, according to data from the London Stock Exchange Group. The company did......

There was HKD2.3 billion, HKD2.2 billion and HKD804.4 million Southbound Trading net inflow to BABA-W (09988.HK), TENCENT (00700.HK) and SMIC (00981.HK).There was HKD174.3 million Southbound Trading net outflow from 3SBIO (01530.HK). For Southbound Trading of Shanghai-Hong Kong Stock Connect, BABA-W (09988.HK) was the most activ......

Stocks | Investment Ratings | Target Prices 3 3SBIO (01530.HK) | Buy | HKD37.58GUSHENGTANG (02273.HK) | Buy | HKD48.28GIANT BIOGENE (02367.HK) | Buy | HKD58.35WUXI XDC (02268.HK) | Buy | HKD74INNOVENT BIO (01801.HK) | Buy | HKD110.62SINO BIOPHARM (01177.HK) | Buy | HKD9.4~AAStocks Financial NewsWeb Site: www.aastocks.com...

There was HKD1 billion, HKD993.1 million and HKD325.5 million Southbound Trading net inflow to XIAOMI-W (01810.HK), CNOOC (00883.HK) and 3SBIO (01530.HK).There was HKD1.4 billion, HKD955.8 million and HKD628 million Southbound Trading net outflow from SMIC (00981.HK), BABA-W (09988.HK) and HUA HONG SEMI (01347.HK).For Southbound......

There was HKD646 million and HKD75.5 million Southbound Trading net inflow to XIAOMI-W (01810.HK) and 3SBIO (01530.HK).There was HKD1.2 billion, HKD711.9 million and HKD473.4 million Southbound Trading net outflow from TENCENT (00700.HK), SMIC (00981.HK) and HUA HONG SEMI (01347.HK).For Southbound Trading of Shanghai-Hong Kong S......